Pharmacy Medical News about Diabetes Mellitus, Type 2 Metformin Pioglitazone

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM
Current Medical Research and Opinion, 10/22/09

Perez A et al. – Overall, treatment with pioglitazone/metformin FDC demonstrated greater efficacy than its individual components. The FDC therapy was well tolerated, with reduced or similar adverse event rates compared with each individual monotherapy.

<< Previous
APP Pharmaceuticals Receives Approval for the First Generic...

Next >>
Cephalon Notified of Generic Filing for Armodafinil Tablets

Pioglitazone Compared with Metformin Increases Pericardial Fat Volume in Patients with Type 2 Diabetes Mellitus
Journal of Clinical Endocrinology and Metabolism, 11/17/09 Relevance Score: 96%

Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes
Diabetes, Obesity and Metabolism, 11/12/09 Relevance Score: 96%

Lactic Acidosis Associated With Metformin in a Patient With Type 2 Diabetes With No Contraindication
The Endocrinologist, 11/13/09 Relevance Score: 94%

Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity
Current Medical Research and Opinion, 10/19/09 Relevance Score: 94%

Adding metformin to insulin did not improve a composite of microvascular and macrovascular disease in type 2 diabetes
Evidence-Based Medicine, 10/07/09 Relevance Score: 94%